Serine hydroxymethyltransferase (SHMT), a ubiquitous representative of the family of fold-type I, pyridoxal 5'-phosphate (PLP) dependent enzymes, catalyzes the reversible conversion of tetrahydrofolate (H(4)PteGlu) and serine to 5,10-CH(2)-H(4)PteGlu and glycine. Together with thymidylate synthase (TS) and dihydrofolate reductase (DHFR), SHMT participates to the thymidylate (dTMP) biosynthetic process. Elevated SHMT activity has been coupled to the increased demand for DNA synthesis in tumour cells. However, SHMT is the only enzyme of the thymidylate cycle yet to be targeted by chemotherapeutics. In this study, the interaction mode of SHMT with pemetrexed, an antifolate drug inhibiting several enzymes involved in folate-dependent biosynthetic pathways, was assessed. The mechanism of SHMT inhibition by pemetrexed was investigated in vitro using the human recombinant protein. The results of this study showed that pemetrexed competitively inhibits SHMT with respect to HeteGlu with a measured K(i) of 19.1 +/- 3.1 mu M; this value was consistent with a K(d) of 16.9 +/- 5.0 mu M, measured by isothermal titration calorimetry. The binding mode of pemetrexed to SHMT was further investigated by molecular docking. The calculated interaction energy of pemetrexed in the active site of SHMT was -7.48 kcal/mol, and the corresponding predicted binding affinity was 36.3 mu M, in good agreement with K(d) and K(i) values determined experimentally. The results thus provide insights into the mechanism of action of this antifolate drug and constitute the basis for the rational design of more selective inhibitors of SHMT. (C) 2011 Elsevier Masson SAS. All rights reserved.

In silico and in vitro validation of serine hydroxymethyltransferase as a chemotherapeutic target of the antifolate drug pemetrexed / Daidone, Frederick; Florio, Rita; Rinaldo, Serena; Contestabile, Roberto; DI SALVO, Martino Luigi; Cutruzzola', Francesca; Bossa, Francesco; Paiardini, Alessandro. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - STAMPA. - 46:5(2011), pp. 1616-1621. [10.1016/j.ejmech.2011.02.009]

In silico and in vitro validation of serine hydroxymethyltransferase as a chemotherapeutic target of the antifolate drug pemetrexed

DAIDONE, FREDERICK;FLORIO, Rita;RINALDO, Serena;CONTESTABILE, Roberto;DI SALVO, Martino Luigi;CUTRUZZOLA', Francesca;BOSSA, Francesco;PAIARDINI, ALESSANDRO
2011

Abstract

Serine hydroxymethyltransferase (SHMT), a ubiquitous representative of the family of fold-type I, pyridoxal 5'-phosphate (PLP) dependent enzymes, catalyzes the reversible conversion of tetrahydrofolate (H(4)PteGlu) and serine to 5,10-CH(2)-H(4)PteGlu and glycine. Together with thymidylate synthase (TS) and dihydrofolate reductase (DHFR), SHMT participates to the thymidylate (dTMP) biosynthetic process. Elevated SHMT activity has been coupled to the increased demand for DNA synthesis in tumour cells. However, SHMT is the only enzyme of the thymidylate cycle yet to be targeted by chemotherapeutics. In this study, the interaction mode of SHMT with pemetrexed, an antifolate drug inhibiting several enzymes involved in folate-dependent biosynthetic pathways, was assessed. The mechanism of SHMT inhibition by pemetrexed was investigated in vitro using the human recombinant protein. The results of this study showed that pemetrexed competitively inhibits SHMT with respect to HeteGlu with a measured K(i) of 19.1 +/- 3.1 mu M; this value was consistent with a K(d) of 16.9 +/- 5.0 mu M, measured by isothermal titration calorimetry. The binding mode of pemetrexed to SHMT was further investigated by molecular docking. The calculated interaction energy of pemetrexed in the active site of SHMT was -7.48 kcal/mol, and the corresponding predicted binding affinity was 36.3 mu M, in good agreement with K(d) and K(i) values determined experimentally. The results thus provide insights into the mechanism of action of this antifolate drug and constitute the basis for the rational design of more selective inhibitors of SHMT. (C) 2011 Elsevier Masson SAS. All rights reserved.
2011
antifolate; drug design; pemetrexed; pleural mesothelioma; serine hydroxymethyltransferase; shmt
01 Pubblicazione su rivista::01a Articolo in rivista
In silico and in vitro validation of serine hydroxymethyltransferase as a chemotherapeutic target of the antifolate drug pemetrexed / Daidone, Frederick; Florio, Rita; Rinaldo, Serena; Contestabile, Roberto; DI SALVO, Martino Luigi; Cutruzzola', Francesca; Bossa, Francesco; Paiardini, Alessandro. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - STAMPA. - 46:5(2011), pp. 1616-1621. [10.1016/j.ejmech.2011.02.009]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/377566
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 51
social impact